Real Brands Files for DEA License for Psychedelics Psychedelics Market Size Expected to Reach $10.75 Billion by 2027
North Providence, RI, March 24, 2022 (GLOBE NEWSWIRE) — Real Brands Inc. (OTCQB: RLBD), a multi-brand owner, formulator, extractor and manufacturer of branded hemp-derived CBD products, begins its expansion to become a premier provider of medical psychedelics. As part of Phase 1 laying the groundwork for medical psychedelics market entry, Real Brands has partnered with consulting firm Marcu & Arora to seek a license from the U.S. Drug Enforcement Agency (DEA) to psychedelics, including defining application protocols and guiding formulation research and development. Additionally, Real Brands will apply to the DEA for permission to process and handle psychedelics, and it has requested the state of Rhode Island to prescribe, distribute, store, and ship controlled substances.
“We continue to research and develop medical psychedelics because current traditional mental health care treatments are often ineffective and have serious negative side effects,” said Thom Kidrin, CEO of Real Brands. “Revolutionary breakthroughs in medicine, pharmacology and behavioral neuroscience have revealed the vast potential of psychedelic and empathogenic drugs as highly effective therapies. We engaged Marcu & Arora to help us navigate the complicated DEA licensing process for psychedelic research, application protocols, and all aspects of formulation R&D. We hope to become the first in Rhode Island to be licensed.
Kidrin noted, “Dr. Jahan Marcu and Dr. Nigam B. Arora are two of the most knowledgeable experts in the fledgling psychedelic industry. With over 30 years of combined experience in chemistry, pharmacology, research, communications, government relations, advocacy and entrepreneurship, we believe their ability to navigate the federal regulatory and research environments is unmatched. Additionally, Marcu & Arora’s network of PhD scientists, physicians, lawyers, standards experts and venture capital firms specializing in these areas provides us with additional resources that we can leverage to effectively develop our psychedelic business with the highest standards.
Previously, research on psychedelics was prohibited by federal agencies due to their classification as Schedule I substances. Federal agencies are now in the process of allowing the controlled production of certain Schedule I substances to for extended research purposes.
“Fortunately, federal agencies have recently begun to acknowledge the results of the limited studies that have been done and the greater body of anecdotal evidence that indicates that psychedelics hold promise for the treatment of certain medical conditions such as depression, PTSD and traumatic brain injury,” said Jahan Marcu, PhD, founding partner at Marcu & Arora. “We believe Real Brands can successfully navigate the Schedule 1 substance research authorization process. The study concepts that Real Brands pursues will have the potential to become breakthrough solutions for drug-based treatment. entheogen of certain mental health conditions with minimal risk.
Real Brands develops a variety of formulations for psychedelics, including low-dose or “micro-dosage” delivery forms. Microdosing is the practice of consuming very low sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin (found in some mushrooms). There are a few scientific papers and a host of anecdotal stories reporting that a wide range of people have experienced benefits in treating PTSD, anxiety, addiction recovery, depression and have done the experiencing increased creativity and an enhanced sense of happiness. Real Brands will explore psychedelic-assisted therapies, based on compounds such as psilocybin, mescaline and N,N-dimethyltryptamine, which are found in nature and have been used by indigenous populations for millennia.
“Just as there has been a sea change in the research and acceptance of cannabis for medical purposes, we believe that psychedelics are the next wave of pharmaceuticals ready to be developed,” Kidrin remarked. “In the midst of unprecedented societal challenges associated with overlapping mental health crises and a strained healthcare system, we stand on the brink of profound change. This previously untapped and underexplored class of drugs is at the center of a development renaissance where client-centered, evidence-based interventions are urgently sought by patients and providers as well as stakeholders. institutional and governmental. Real Brands is positioned to take advantage of new clinical research and the opportunity before us, to produce and deliver safe, nature-based product formulations that will effectively treat mental health issues.
Research firm Research And Markets forecasts the market size for psychedelic drugs to reach US$10.75 billion by 2027, from US$4.75 billion in 2020, with a CAGR of 12.36% in 2021-2027. Fairfield Market Research said traditional drug treatments and therapies are not effectively combating the mental health crisis. Fairfield argues that psychedelics may see an increase in demand in the coming years. “These statistics taken together [about mental health rates] are expected to generate demand for psychedelic drugs as mental health diagnostic, therapeutic and awareness programs gain prominence at individual and institutional levels.
Positive results from various clinical trials with psychedelics have been associated with a large amount of capital investment in psychedelic biotechnology companies. As more companies see the potential of psychedelics to treat mental health issues, the field is expanding.
# # #
About Real Brands Inc.
Real Brands is a multi-brand owner, formulator, extractor and manufacturer of branded hemp-derived CBD products to improve targeted areas of health and wellness for athletes, consumers and pets. Real Brands is the result of a 2020 merger with Canadian American Standard Hemp Inc. (CASH) which brought together the extraction and processing of CBD oil/isolate from hemp on an industrial scale, the sale in wholesale of CBD oils and isolates, as well as the production and sale of many hemp-derived products. Consumer CBD brands of smokable, edible and topical products. Its proprietary Halo 5 chromatography extraction technology mass-produces highly purified material and precise pharmaceutical-grade molecular separation at dramatically reduced costs, resulting in more affordable precision-formulated products. Visit https://realbrands.com/. Consumer product lines are available at www.phazesports.com, www.wabrands.com and www.americanstandardhemp.com.
This press release contains certain forward-looking statements and information relating to Real Brands, Inc. (the “Company”) that are based on the Company’s management’s current beliefs, as well as assumptions made by the Company and information currently available. its disposition. . These statements reflect the Company’s current views with respect to future events and are subject to certain assumptions, including those described in this release. If one or more of these underlying assumptions proves incorrect, actual results may vary materially from those described herein as “should”, “could”, “will”, “anticipate”, “believe”, “have the intention to”, “plan”, “could”, “potentially”, “target” or “expect”. Other factors that could also cause actual results to differ materially relate to the global COVID-19 crisis and other risk factors described in our public filings. The Company does not intend to update these forward-looking statements. The content of the websites referenced above is not incorporated herein.
Media Relations: Accentuate PR, Julie Shepherd 847 275 3643, email@example.com Sales/Investors: 781-366-7400, firstname.lastname@example.org